Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The McGill University Health Center (MUHC) Division of Cardiology, with funding from the
Canadian Institute of Health Research, is performing this randomized controlled trial to
determine which dual antiplatelet therapy (DAPT), ticagrelor + aspirin (T+A) or clopidogrel
and aspirin (C+A), is the most effective and safest for our patients. While the PLATO trial
reported that T+A was superior, the prespecified group of North American patients (about 1/10
of the total study sample) actually did better with C+A, although this difference was not
statistically significant. When the FDA approved T, they also stated: "Lack of Robustness of
PLATO Superiority with Failure in the US Makes a Confirmatory Study Mandatory." As no
confirmatory study has been done, this TC4 study aims to fill that void.
Study design: A cluster randomization design, so all patients will receive either T+A or C+A,
depending on the month they arrive at the MUHC when they start their DAPT. We will follow
patients through their electronic health records. The patients have no follow-up visits for
this research project.
Phase:
Phase 4
Details
Lead Sponsor:
McGill University Health Center McGill University Health Centre/Research Institute of the McGill University Health Centre